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Abstract The aim of the study was to evaluate the fre-
quency of occurrence of pituitary failure following neuro-
surgery andthe efﬁcacy oftranssphenoidal tumour resection
in acromegalic patients. We retrospectively evaluated
85 patients (60 female and 25 male), of mean age
43.9 ± 13.2 years, treated by transsphenoidal neurosur-
gery. Macroadenoma and microadenoma of pituitary were
found in 66 (77.6%) and 19 (22.4%) of these patients,
respectively. Criteria of cure following neurosurgery were:
basal GH\2.5 lg/l, GH at 120 min in OGTT\1.0 lg/l
and serum concentration of IGF-1 within normal ranges for
age and sex. After surgery 32 patients (37.6%) were cured
and 53 patients (62.4%) required somatostatin analogue
treatment. In patients cured by surgery, lower levels of basal
GH (P\0.05), IGF-1 (P\0.001), GH at 120 min in
OGTT and smaller size of pituitary tumour (P\0.05) were
found atdiagnosis, ascompared topatientsin whom surgery
was unsuccessful. Signiﬁcant correlation between basal
serum level of GH at diagnosis and size of pituitary tumour
was found (P\0.001). Invasive tumours were found in 45
of 53 (84.9%) patients not cured and in only 8 of 32 (25.0%)
patients cured (P\0.001). Impaired function of pituitary
anterior lobe after surgery was observed in 30% and 4% of
patients with macro- and microadenoma, respectively
(P\0.05). The efﬁcacy of neurosurgery is affected by
concentration of basal serum GH and IGF-1, GH at 120 min
in OGTT, tumour size and invasiveness. Hypopituitarism
after surgery is more frequent in patients with macroade-
noma. Pituitary insufﬁciency, as a consequence of surgery,
was found in 21% of patients with normal pituitary function
prior to operation.
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Introduction
Acromegaly is a rare chronic disease occurring with a
populationprevalenceof60permillionandincidenceof3–4
per million a year [1]. In almost all cases, it is caused by
growth hormone (GH)—secreting pituitary adenoma, pro-
ducing an excess of GH. In turn, growth hormone stimulates
production of insulin-like growth factor-1 (IGF-1). There-
fore, in acromegaly, its concentration is elevated. Progres-
sive somatic disﬁgurement (mainly involving face and
extremities) and systemic complications such as arterial
hypertension, cardiomyopathy, congestive heart failure,
arrhythmias, sleep apnea and ventilatory dysfunction, mul-
tinodular goitre, menstrual irregularities, hyperprolactina-
emia, diabetes mellitus, arthropathy, peripheral neuropathy,
colon polyps are the main clinical manifestations of acro-
megaly [2, 3]. Increased risk of cancer (particularly colon
cancer) is being considered [4–6]. Acromegaly is associated
with signiﬁcant morbidity and increased mortality as com-
pared to the general population [1, 7–9]. The mortality rate
foruncontrolleddiseaseactivityis2–4timeshigherthanthat
of the general population, principally because of higher risk
of cardiovascular disease [8]. This mortality ratio can be
decreased if the elevated GH and IGF-1 levels are success-
fully normalized. The criteria for diagnosing acromegaly
are: elevated serum GH and IGF-1 concentration above
normal range for age and gender, and no inhibition of GH
concentration in OGTT (75 g of glucose) below 1.0 lg/l.
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remains the primary therapy for most patients with acro-
megaly. If surgery fails to correct GH/IGF-1 hypersecre-
tion, medical treatment with somatostatin analogues,
dopaminergic agonists and/or radiotherapy can be applied.
A GH antagonist (pegvisomant) may be used in patients
resistant to somatostatin analogues [11]. The therapeutic
goals in acromegaly are to eliminate morbidity and to
reduce mortality. Both objectives can be achieved by
removing tumour mass or controlling its growth. The
deﬁnitions of ‘‘cure’’ and disease control are: basal GH
concentration below 2.5 lg/l, nadir GH concentration at
120 min of OGTT below 1.0 lg/l and normal IGF-1 for
age and gender [10].
The aim of this study was to examine the incidence rate
of pituitary failure following neurosurgery in acromegalic
patients. The dependence of the efﬁcacy of transsphenoidal
tumour resection on pre-operative factors, such as tumour
size and serum GH and IGF-1 concentration, were also
evaluated.
Materials and methods
Our study concerned acromegalic patients treated at the
Department of Endocrinology, Jagiellonian University
Hospital in Krakow, a regional centre for acromegalic
patients, between 1986 and 2009. Of these, 85 patients (60
female and 25 male), of mean age 43.9 ± 13.2 years, were
treated by transsphenoidal neurosurgery. In all 85 patients
no somatostatin analogue treatment nor radiotherapy had
preceded neurosurgery. Macroadenoma of the hypophysis
was found in 66 (77.6%) patients, while microadenoma
was found in 19 (22.3%) patients. Acromegaly was usually
diagnosed within 7–10 years of the onset of disease. The
mean age of patients at diagnosis of acromegaly was
43.9 ± 13.2 years. Two groups of patients were analysed:
those cured by surgery and those in whom surgery was not
successful.
The serum concentration of GH and IGF-1 was mea-
sured using IRMA (DiaSorin) and RIA (Biosource) meth-
ods, respectively. The concentration of pituitary and
thyroid hormones before and after surgery were estimated.
Measurements of ACTH, FSH, LH, TSH serum concen-
trations were performed using immunoradiometric assay
(IRMA), fT3 and fT4 serum concentration was measured by
electrochemiluminescent (ECL) method. The prevalence of
diabetes insipidus was stated based on plasma and urine
osmolality. In 45 of the 85 patients studied full preopera-
tive pituitary function evaluation was completed. The
effect of surgery on pituitary hormonal sufﬁciency was
assessed in this subgroup.
For statistical analysis, basic statistics, Shapiro–Wilk, U
Mann–Whitney and v
2 tests of the Statistica v.8.0 package
were used.
Results
In the 85 acromegalic patients a higher frequency of
macroadenoma (66/85,77.6%) was observed. The size of
pituitary adenoma at diagnosis in patients treated by neu-
rosurgery is shown in Table 1. The mean basal serum GH
concentration prior to treatment was 33.3 ± 40.5 lg/l,
mean concentration of GH at 120 min in OGTT was
20.3 ± 31.1 lg/l, and mean level of IGF-1 was 818.8 ±
346.9 ng/ml. After surgery 32 patients (38%) were cured
and 53 patients (62%) required further treatment with
somatostatin analogues. The efﬁcacy of surgery was
dependent on the size of pituitary adenoma (Fig. 1).
In 45 (85%) of not cured patients and in 8 (25%) patients
in whom surgery was successful invasive tumour was
identiﬁed on preoperative imaging (Fig. 2), which affected
the outcome of surgery (P\0.001).
A high frequency of mixed adenoma in acromegalic
patients was observed (monohormonal adenoma 29.6%,
polyhormonal adenoma 70.5%).
The prevalence of pituitary adenoma secreting other
hormones than GH was as follows: PRL-56.8% of acro-
megalic patients, ACTH-20.5% of these patients, FSH-
15.9%, a–subunit-11.6%, TSH-11.4% and LH-6.82% of
Table 1 Size of pituitary adenoma at diagnosis in patients treated by
neurosurgery (n = 85)
Tumour size [mm] N %
B10 19 22.4
11–20 40 47.1
21–30 16 18.8
31–40 6 7.1
[40 4 4.7
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Fig. 1 The efﬁcacy of surgery in micro- and macroadenoma of the
pituitary
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123these patients. No difference in surgery outcome between
patients with mono and plurihormonal tumours (P[0.05)
was found. Permanent (over 3 months) impairment of
posterior lobe function (diabetes insipidus) was observed in
16.7 and 22.2% patients with macro- and microadenoma,
respectively.
Impaired function of pituitary-adrenal, pituitary-thyroid
and pituitary–gonadal axis were proven in 24 (28.2%), 22
(25.9%) and 18 (21.1%) studied patients, respectively.
Signiﬁcant difference (P\0.05) between frequency of
impaired function of the pituitary anterior lobe in patients
with micro- and macroadenoma was observed (Table 2). In
the case of the posterior lobe, no such relation was
observed (P[0.05).
Normal pituitary function prior to surgery was observed
in thirty-three of the 45 patients in whom evaluation of
pituitary hormonal sufﬁciency was complete. Following
surgery, seven (21%) of these 33 patients were diagnosed
as having hypopituitarism, poly- or monoaxial. In all
patients with hypopituitarism the adrenal axis was
impaired, which was the most frequent sequel (Fig. 3).
There were 12 patients with poly- or mono-axial hypo-
pituitarism prior to surgery. Gonadal monoaxial insufﬁ-
ciency was the most frequent failure found prior to surgery
(11 patients). In one case we diagnosed thyroidal mono-
axial pituitary failure prior to surgery.
In 5 out of 12 patients with poly- or mono-axial hypo-
pituitarism prior to surgery, worsening of pituitary function
was found post-surgery, while in 1 patient no change was
observed. In 6 patients normal sufﬁcient pituitary function
was restored (Fig. 4). Worsening of pituitary function was
deﬁned as failure of a higher number of hormonal axes than
prior to surgery.
A statistically signiﬁcant correlation between basal
serum GH concentration and the size (largest diameter) of
pituitary tumour was found (P\0.001).
We compared two groups of patients, cured and not
cured by surgery. At diagnosis, statistically signiﬁcant
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Fig. 2 Tumour invasiveness, as
based on MRI imaging, in
acromegalic patients not cured
and cured after transsphenoidal
surgery
Table 2 The relationship between the pituitary adenoma size and the
frequency of deﬁcient function of anterior lobe of pituitary after
surgery
Size of adenoma Normal
function n (%)
Impaired
function n (%)
Total
n (%)
Microadenoma 16 (18.8) 3 (3.5) 19 (22.4)
Macroadenoma 36 (42.4) 30 (35.3) 66 (77.6)
Total 52 (61.1) 33 (38.8) 85 (100)
Pearson’s v
2 test: 5.466, P\0.05
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Fig. 3 Normal pituitary function and hypopituitarism after trans-
sphenoidal surgery in patients with sufﬁcient pituitary function prior
to operation
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123differences between median values of basal GH concen-
tration (P\0.05), GH concentration at 120 min in OGTT
(P\0.05), IGF-1 concentration (P\0.001) and the size
(largest diameter) of pituitary tumour (P\0.05), were
found between these groups. (Figs. 5, 6, 7, 8).
The mean values (X ± SD) of GH concentration in
groups of patients cured and not cured were 29.3 ± 39.5
and 36.6 ± 33.9 lg/l, respectively. The mean values of
IGF-1 concentration in groups of patients cured and not
cured were 489.1 ± 264.0 and 981.1 ± 361.9 ng/ml,
respectively. The average concentrations of GH at 120 min
of OGTT in these groups of patients were 8.7 ± 6.2 and
48.1 ± 49.7 lg/l, respectively.
The mean values of the largest diameter of pituitary
adenoma in the group of patients cured by surgery and the
group of patients in whom surgery was unsuccessful, were
10.8 ± 10.0 and 15.5 ± 12.6 mm, respectively. Signiﬁcant
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Fig. 4 Changes in pituitary hormonal function after surgery in
patients with hypopituitarism prior to operation
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Fig. 5 Basal serum GH concentration at diagnosis in patients not
cured and cured by pituitary adenoma surgery
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Fig. 6 Basal serum IGF-1 concentration at diagnosis in patients not
cured and cured by pituitary adenoma surgery
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Fig. 7 GH concentration at 120 min of OGTT in patients not cured
and cured by pituitary adenoma surgery
160 Pituitary (2011) 14:157–162
123inﬂuence of the size of pituitary adenoma on neurosurgery
outcome was found (P\0.05).
Discussion
Acromegaly is a rare disease caused by growth hormone
excess, in majority of cases due to a GH—secreting pitu-
itary adenoma. The therapeutic goals in acromegaly are
to eliminate morbidity and to reduce mortality. These can
be achieved by removing tumour mass (transsphenoidal
surgery) or by controlling its growth (somatostatin ana-
logues, dopaminergic agonists, GH antagonist, and/or
radiotherapy) [11–14].
In our study we observed that factors, such as basal GH
concentration, GH concentration at 120 min. of OGTT,
IGF-1 concentration as well as the size of pituitary tumour
prior to surgery, signiﬁcantly inﬂuence the degree of dis-
ease control after neurosurgery.
In microadenoma the efﬁciency of neurosurgical treat-
ment ranges between 61–91% of all cases operated on, as
compared to macroadenoma 23–53%, in which the success
of surgery depends on the tumour size, its location and on
initial concentration of GH [15–16].
In our studied group, the results of surgery in patients
with larger pituitary tumours were worse as compared to
patients with microadenoma. Patients with macroadenoma
had higher basal level of GH than 2.5 lg/l, IGF-1 above
the normal limits for age and gender, so did not meet the
criteria for cure. A statistically signiﬁcant difference in the
size of tumour (the largest diameter) between groups of
cured and not cured patients was found.
The study of Barker et al. [17] and Ciric et al. [18]
revealed that transsphenoidal surgery of pituitary adenoma
involved mortality of around 0.9% in the perisurgery
period.
According to Salaun et al. [19], the poor prognosis
factors are: young age, prior to surgery growth hormone
level of over 50 ng/ml, invasive adenomas, monohormonal
status in immunocytochemistry and lack of decrease in
postoperative growth hormone level during the glucose
tolerance test. In our study, the monohormonal status as a
prognostic factor was not conﬁrmed.
Hypopituitarism in acromegalic patients may result from
compression of the pituitary by the tumour or result from
neurosurgical treatment. Therefore, the pituitary function
should be estimated in these patients prior to and after
surgery.
In our study, impaired function of the anterior lobe of
the pituitary was observed more frequently in patients with
macroadenoma than in those with microadenoma, unlike
the case of impaired function of the posterior lobe after
surgery, which was found more frequently in patients with
microadenoma than in those with macroadenoma.
According to Tomlinson et al. and Rosen et al. [20, 21],
hypopituitarism observed in 10–40% of acromegaly
patients leads to increased mortality rate despite optimal
hormonal substitution. In 2009 Sherlock et al. [22] evalu-
ated the inﬂuence of radiotherapy, deﬁcient secretion of
ACTH and treatment with hydrocortisone (HC) on the
mortality rate, observing increased mortality rate in acro-
megaly patients with ACTH deﬁciency following radio-
therapy. They also observed that administration of high
doses of hydrocortisone (over 25 mg per day) corre-
sponded with increased mortality, compared with admin-
istration of lower doses of this medication. Based on this
observation they stated that the dose of hydrocortisone has
to be carefully titrated in these patients.
Reported incidence of new hypopituitarism following
neurosurgery in 21% of our patients is possibly due to
relatively wide time range when operations were carried
out and related to continuously increasing experience of
our neurosurgery team. The impact of subspecialization in
pituitary surgery on its efﬁcacy is well known [23].
Recently, Gondim et al. (2010) reported pituitary failure in
9 of 67 (13.4%) transsphenoidally operated patients with
acromegaly [24].
Rieger et al. examined 44 acromegaly patients who
underwent surgery [25]. In 25 of these patients invasion of
the sphenoid sinus was found. Interestingly, the level of
GH prior to surgery appeared to be a more important
indicator of tumour invasiveness than IGF-1 concentration.
The high GH concentration prior to and after surgery
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Fig. 8 Size (largest diameter) of pituitary adenoma at diagnosis in
patients not cured and cured by pituitary adenoma surgery
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123correlated with suprasellar growth of the tumour. Thus,
according to these authors, GH concentration should be
considered as a prognostic factor in selecting further
treatment of pituitary adenoma.
Conclusion
Based on our observations, we found that the efﬁcacy of
transsphenoidal surgery in acromegalic patients was
affected by basal serum GH and IGF-1 concentration, GH
concentration at 120 min in OGTT, tumour size, and
invasiveness. Hypopituitarism after surgery is more fre-
quent in patients with macroadenoma. Following surgery,
pituitary insufﬁciency was found in 21% of patients with
normal pituitary function prior to operation. In some 50%
of patients with monoaxial insufﬁciency of pituitary prior
to surgery, restoration of pituitary function was observed.
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